Halozyme Therapeutics Stock Price

-0.16 (-0.53%)
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Halozyme Therapeutics Incorporated HALO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.16 -0.53% 30.06 17:12:30
Close Price Low Price High Price Open Price Previous Close
30.06 29.885 30.85 30.39 30.22
Bid Price Ask Price Spread News
29.80 30.16 0.36 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
12,922 1,953,677 $ 30.32 $ 59,238,865 1,183,951 12.71 - 30.88
Last Trade Time Type Quantity Stock Price Currency
16:34:18 priorref 15,555 $ 30.06 USD

Halozyme Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 4.12B 137.03M 121.99M $ 195.99M $ -21.44M -0.50 -192.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% -115.83k 8.30%

more financials information »

Halozyme Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical HALO Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week28.4430.8828.17529.451,710,3081.625.7%
1 Month26.6530.8825.1727.791,092,3943.4112.8%
3 Months27.1730.8825.1727.921,010,8372.8910.64%
6 Months19.4230.8819.3626.041,210,56110.6454.79%
1 Year15.3630.8812.7121.581,453,39214.7095.7%
3 Years17.8230.8812.7119.391,059,84212.2468.69%
5 Years13.9530.886.9615.931,197,09116.11115.48%

Halozyme Therapeutics Description

Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.